Bantam Pharmaceutical Pipeline – BTM 10xx

Anticipated IND Filing Q2, 2018

Bantam Pharmaceutical Pipeline – Follow On


Highlights of Bantam’s Current Development Candidate

  • Small molecule compound with nanomolar in vitro potency against a wide range of cancer cells; no or limited activity in normal cells
  • No activity against a broad spectrum of biochemical targets
  • Excellent rodent oral pharmacokinetics and well tolerated in vivo Mechanism of action associated with a reduction in levels of key oncogenic proteins in vitro and in vivo
  • Sustained tumor regressions in human B cell lymphoma xenografts
“Sustained regressions with no toxicity observed on BTM-10xx administration in human tumor xenografts”

Interested in contacting Bantam regarding further information?